ClinicalTrials.Veeva

Menu

Vitamin D Supplementation and TB

C

Cornell University

Status

Unknown

Conditions

Immunity
Tuberculosis
Vitamin D

Treatments

Dietary Supplement: Vitamin D (600 IU)
Dietary Supplement: Vitamin D (4000 IU)
Dietary Supplement: Vitamin D (2000 IU)
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01992263
IRB #: 1304003801

Details and patient eligibility

About

The goal of this study is to understand the effects of vitamin D supplementation on immunological outcomes among patients with tuberculosis.

Full description

In this randomized trial, the investigators will enroll 200 adults with active pulmonary tuberculosis (TB; among whom 40 have HIV co-infections) at the time of TB diagnosis in S India. The intervention will include daily vitamin D supplementation in 3 treatment arms (600, 2000, and 4000 IU vitamin D), compared to placebo, for 12 months. The investigators' primary objectives are to assess how vitamin D supplementation affects immunity (immunological markers, immune competence) and serum vitamin D levels. Secondary outcomes include TB treatment outcomes (successful sputum smear conversion, relapse) in all patients, and human immunodeficiency virus (HIV) disease progression among a subset of patients with HIV co-infection.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Active TB diagnosis by GeneXpert
  • HIV infection status (according to AMC HIV clinic medical records of enzyme-linked immunosorbent assay [ELISA] results)

Exclusion criteria

  • Children (<18 years of age)
  • 60 years of age
  • Pregnant at baseline
  • Other severe complications or illnesses requiring hospitalization
  • Received TB treatment for greater than 4 weeks in the past 5 years
  • Refused to participate
  • Residing in a geographic location > 1 hour from AMC (by public transit)

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

200 participants in 4 patient groups, including a placebo group

Vitamin D (600 IU)
Experimental group
Treatment:
Dietary Supplement: Vitamin D (600 IU)
Vitamin D (2000 IU)
Experimental group
Treatment:
Dietary Supplement: Vitamin D (2000 IU)
Vitamin D (4000 IU)
Experimental group
Treatment:
Dietary Supplement: Vitamin D (4000 IU)
Placebo
Placebo Comparator group
Treatment:
Other: Placebo

Trial contacts and locations

2

Loading...

Central trial contact

Saurabh Mehta, MBBS, ScD; Elaine Yu, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems